Spots Global Cancer Trial Database for budigalimab
Every month we try and update this database with for budigalimab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients | NCT06119217 | Pancreatic Canc... | TTX-030, nab-pa... TTX-030, budiga... Nab-Paclitaxel ... | 18 Years - | Trishula Therapeutics, Inc. | |
| A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors | NCT06158958 | Solid Tumors | ABBV-303 Budigalimab | 18 Years - | AbbVie | |
| A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors | NCT02988960 | Advanced Solid ... | ABBV-927 ABBV-927 ABBV-181 | 18 Years - | AbbVie | |
| TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers | NCT04306900 | Solid Tumor, Ad... | TTX-030, budiga... TTX-030, budiga... TTX-030 and mFO... TTX-030 and bud... TTX-030, budiga... TTX-030 and pem... TTX-030, nab-pa... Budigalimab and... | 18 Years - 110 Years | Trishula Therapeutics, Inc. | |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors | NCT05599984 | Advanced Solid ... | ABBV-706 Cisplatin Budigalimab Carboplatin | 18 Years - | AbbVie | |
| Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis | NCT04807972 | Pancreatic Canc... | ABBV-927 Budiglimab modified FOLFIR... | 18 Years - 75 Years | AbbVie | |
| A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors | NCT06158958 | Solid Tumors | ABBV-303 Budigalimab | 18 Years - | AbbVie | |
| A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer | NCT03639194 | Small Cell Lung... | ABBV-011 Budigalimab | 18 Years - | AbbVie | |
| Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors | NCT03821935 | Advanced Solid ... | Livmoniplimab Budigalimab | 18 Years - | AbbVie | |
| Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) | NCT05822752 | Hepatocellular ... | Budigalimab Livmoniplimab Lenvatinib Sorafenib | 18 Years - | AbbVie | |
| Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors | NCT03821935 | Advanced Solid ... | Livmoniplimab Budigalimab | 18 Years - | AbbVie |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
